These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31523593)

  • 1. Marketing of drugs for rare diseases is speeding up in China: Looking at the example of drugs for mucopolysaccharidosis.
    Kang Q; Hu J; Yang N; He J; Yang Y; Tang M; Jin C
    Intractable Rare Dis Res; 2019 Aug; 8(3):165-171. PubMed ID: 31523593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on China's national policies regarding rare diseases.
    Ying Z; Gong L; Li C
    Intractable Rare Dis Res; 2021 Aug; 10(3):148-153. PubMed ID: 34466336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elosulfase alfa: first global approval.
    Sanford M; Lo JH
    Drugs; 2014 Apr; 74(6):713-8. PubMed ID: 24700469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis on the Marketing Trend and Approval Lag of Imported Orphan Drugs from 2010 to 2021 in China.
    Peng F; Zheng H
    Ther Innov Regul Sci; 2023 Nov; 57(6):1314-1321. PubMed ID: 37651044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends and Characteristics of New Drug Approvals in China, 2011-2021.
    Su L; Liu S; Li G; Xie C; Yang H; Liu Y; Yin C; Chen X
    Ther Innov Regul Sci; 2023 Mar; 57(2):343-351. PubMed ID: 36322325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Incentive Policies and Initiatives on Orphan Drug Development in China: Challenges, Reforms and Implications.
    Zhao Z; Pei Z; Hu A; Zhang Y; Chen J
    Orphanet J Rare Dis; 2023 Jul; 18(1):220. PubMed ID: 37501126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elosulfase Alfa: a review of its use in patients with mucopolysaccharidosis type IVA (Morquio A syndrome).
    Lyseng-Williamson KA
    BioDrugs; 2014 Oct; 28(5):465-75. PubMed ID: 25200032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases.
    Xu K; Coté TR
    Brief Bioinform; 2011 Jul; 12(4):341-5. PubMed ID: 21357612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the national system for rare diseases in China from the point of drug access: progress and challenges.
    Qiao L; Liu X; Shang J; Zuo W; Xu T; Qu J; Jiang J; Zhang B; Zhang S
    Orphanet J Rare Dis; 2022 Sep; 17(1):352. PubMed ID: 36088349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laronidase.
    BioDrugs; 2002; 16(4):316-8. PubMed ID: 12196045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elosulfase alfa in the treatment of mucopolysaccharidosis type IVA: insights from the first managed access agreement.
    Stevens B; Kenny T; Thomas S; Morrison A; Jarrett J; Jain M
    Orphanet J Rare Dis; 2021 Sep; 16(1):394. PubMed ID: 34563214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving access to medicines: lessons from 10 years of drug reforms in China, 2009-2020.
    Mao W; Jiang H; Mossialos E; Chen W
    BMJ Glob Health; 2022 Nov; 7(11):. PubMed ID: 36332928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galsulfase: arylsulfatase B, BM 102, recombinant human arylsulfatase B, recombinant human N-acetylgalactosamine-4-sulfatase, rhASB.
    Drugs R D; 2005; 6(5):312-5. PubMed ID: 16128602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research and development of mAb drugs in China: a look from policy perspectives.
    Jiang R; Sun Y; Ung C; Dong X; Kong X; Hu Y; Shao R
    Hum Vaccin Immunother; 2019; 15(11):2695-2705. PubMed ID: 31116629
    [No Abstract]   [Full Text] [Related]  

  • 16. Elosulfase alfa.
    Haddley K
    Drugs Today (Barc); 2014 Jul; 50(7):475-83. PubMed ID: 25101330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Policy Updates on Access to and Affordability of Innovative Medicines in China.
    Liu GG; Wu J; He X; Jiang Y
    Value Health Reg Issues; 2022 Jul; 30():59-66. PubMed ID: 35235902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current situation of pediatric clinical trials in China: focus on trials for drug marketing application and administrative approval.
    Song L; Jia Y; Ran S; Li B; Xu J; Huo B; Yin N; Ai M; Liu Y
    BMC Pediatr; 2022 Mar; 22(1):144. PubMed ID: 35303815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accessibility of drugs for rare diseases in China: Policies and current situation.
    Yang Y; Kang Q; Hu J; Kong F; Tang M; He J; Jin C
    Intractable Rare Dis Res; 2019 May; 8(2):80-88. PubMed ID: 31218157
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.